Upregulation of SPINK2 in acute myeloid leukemia.

Creative Commons License

Gezer S., Emrence Z., Elverdi T., Ar M. C., Salman Yaylaz B., Paçal F., ...Daha Fazla

Advances in laboratory medicine, cilt.4, sa.1, ss.92-104, 2023 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 4 Sayı: 1
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1515/almed-2022-0047
  • Dergi Adı: Advances in laboratory medicine
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Fuente Academica Plus, CINAHL, Directory of Open Access Journals
  • Sayfa Sayıları: ss.92-104
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objectives

Acute myeloid leukemia (AML) is a highly heterogeneous disease. Although patients can be classified into risk groups based on their genetic changes, the prognosis of disease within these categories varies widely. This situation raises the need to search for new molecular markers related to AML. Serine peptidase inhibitor Kazal type 2 (SPINK2) has recently been reported to be upregulated in AML and associated with poor outcomes by meta-analysis and in a limited number of AML patients.

Methods

We analyzed SPINK2 mRNA expression in 62 patients (45 adult and 17 pediatric) with AML and 11 cell lines using quantitative Real-Time PCR (qRT-PCR). SPINK2 protein level was determined using ELISA in cell lines.

Results

We found that the expression of SPINK2 mRNA and protein levels in AML cell lines (HL60 and NB4) have increased compared to other cell lines (K562, Jurkat and NALM6, MCF7, HeLa, HUVEC, hFOB, 293T, U87). SPINK2 mRNA expression was upregulated in patients with AML compared to controls (p=0.004) and significantly lower in t(8;21)-positive patients compared to negative patients (p=0.0006).

Conclusions

Our results suggest that SPINK2 serves an important role in AML development. Further studies are needed to evaluate SPINK2 expression in AML patients with t(8.21) and investigate to clarify its prognostic value in various subgroups of AML.